Modus Therapeutics - Symbiosis Pharmaceutical Services Starts Producing Sevuparin for Modus’ Future Clinical Development in Sepsis/septic shock
STOCKHOLM, SWEDEN – 12 October 2021: Modus Therapeutics Holding AB (“Modus”), a company developing innovative treatments for patients with high unmet medical needs, announces that Symbiosis Pharmaceutical Services Ltd (“Symbiosis”), a specialist contract manufacturing organization (CMO), has started manufacturing sevuparin drug product securing the supply for the Phase II clinical development in sepsis/septic shock and other conditions driven by systemic inflammation. This follows a recent drug supply agreement between Modus and Symbiosis covering the drug product needs for the Phase II